Atiquity - Investor Profile and Portfolio

ABAC Therapeutics is early stage biopharma developing precision drugs for MDR bacterial infections. It is developing drugs for the precision treatment of MDR Gram-negative infections. The drug development is based on their proprietary drug discovery platform PasNas which is a scalable and multiplex platform capable of effectively unveiling pathogen-specific antibacterial properties of molecules. Its anti-Gram-negative programs include small molecules for A.baumannii in lead optimization stage and for E.coli, K.pneumoniae, and P.aeruginosa in initial stages. The mechanism of action of the drugs has not been revealed as on Aug.2017. The company has raised €16 million Series A funding for development of drug for MDR bacterial infections in Feb 2018.

Developer of ready-to-use kits for in vitro ADME-Tox market segment for research services. It provides cell-based in vitro kits that have patented gel-like cell culture medium, and shipping medium, which preserves cell functionality and viability at room temperature.

DRACONIS PHARMA is a developer of therapeutic solutions for the treatment of therapies for the treatment of cancer, pain, & other diseases. It has developed solutions for treating immune-based diseases such as inflammation, autoimmunity, allergy, cancer, pain, etc. It offers solutions to evaluate, the efficacy, safety, and toxicology of many types of compounds, such as small molecules, proteins, antibodies, RNA-based compounds, vaccines, functional foods, or probiotics. It has developed drug EP4 receptor antagonism for the response of the immune system.

Vivotecnia offers pre-clinical contract research services for biopharma companies. Its main services are general toxicology, inhalation toxicology, genotoxicity, safety pharmacology and efficacy studies Animal species used include rat, mouse, rabbit, dog, guinea pig, mini-pig and non-human primates.